Development and validation of highly selective method for the determination of imatinib mesylate and dexketoprofen trometamol combination in three different media
Braz. J. Pharm. Sci. (Online)
;
56: e18583, 2020. tab, graf
Article
in English
| LILACS
| ID: biblio-1132052
ABSTRACT
Imatinib mesylate is a small molecule used in cancer therapy as a thyrosine kinase inhibitor. Dexketoprofen trometamol is a non-steroidal anti-inflammatory drug that has seen use in cancer therapy in combination with an anticancer drug to minimize tumor size and to reduce pain in patients. In the present study, imatinib mesylate and dexketoprofen trometamol were selected as potential model drugs to be used in combination. A new, simple and selective Ultra Performance Liquid Chromatography method was developed and validated to determine the drug substances in distilled water, in a pH 7.4 phosphate buffer and in Dulbecco's Modified Eagle Medium. The proposed method was developed using a BEH C-18 column with isocratic elution. A mixture of methanolacetonitrile (8020, v/v) and pH 9.5, 0.05 M ammonium acetate were (7030, v/v) used as a mobile phase. Detection was carried out with a flow rate of 0.3 mL/min, a column temperature of 30°C and an injection volume of 20 µL. The method was validated considering linearity, accuracy, precision, specificity, robustness, detection limit and quantitation limit values, and was found to be linear in a range from 0.05 to 20.0 µg/mL for the three different media
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Validation Study
/
Imatinib Mesylate
Type of study:
Diagnostic study
Language:
English
Journal:
Braz. J. Pharm. Sci. (Online)
Journal subject:
Farmacologia
/
Teraputica
/
Toxicologia
Year:
2020
Type:
Article
Affiliation country:
Turkey
Institution/Affiliation country:
Biruni University Faculty of Pharmacy/TR
/
Karadeniz Technical University Faculty of Pharmacy/TR
Similar
MEDLINE
...
LILACS
LIS